rian.ie - Browse

A A A

Limited By:	Subject = Efficacy;

Displaying Results 1 - 25 of 39 on page 1 of 2

Mark

A cognitive occupation-based programme for people with multiple sclerosis: a study to test feasibility and clinical outcomes (2019)

Reilly, Sean; Hynes, Sinéad M.

Mark

A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia (2018)

Maung, Su W.; Leahy, Maeve; O'Leary, Hilary M.; Khan, Irfan; Cahill, Mary R.; Gill...

A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia (2018)

Maung, Su W.; Leahy, Maeve; O'Leary, Hilary M.; Khan, Irfan; Cahill, Mary R.; Gilligan, Oonagh; Murphy, Philip; McPherson, Suzanne; Jackson, Fred; Ryan, Mary; Hennessy, Brian; McHugh, Johnny; Goodyer, Matthew; Bacon, Larry; O'Gorman, Peter; Nee, Aisling; O'Dwyer, Michael; Enright, Helen; Saunders, Jean; O'Keeffe, Denis

Abstract:

This retrospective analysis assessed the response, safety and duration of response to standard dose rituximab 375 mg/m(2) weekly for four weeks as therapy for patients with primary or secondary warm autoimmune haemolytic anaemia (WAIHA), who had failed initial treatment. Thirty-four patients received rituximab for WAIHA in seven centres in the Republic of Ireland. The overall response rate was 70 center dot 6% (24/34) with 26 center dot 5% (9/34) achieving a complete response (CR). The time to response was 1 month post-initiation of rituximab in 87 center dot 5% (21/24) and 3 months in 12 center dot 5% (3/24) of patients. The median duration of follow-up was 36 months (range 6-90 months). Of the patients who responded, 50% (12/24) relapsed during follow up with a median time to next treatment of 16 center dot 5 months (range 6-60 months). Three patients were re-treated with rituximab 375 mg/m2 weekly for four weeks at relapse and responded. There was a single episode of neutropenic ...

http://hdl.handle.net/10379/12686

Mark

A phase i dose-escalation study of msc1992371a, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies (2018)

Graux, Carlos; Sonet, Anne; Maertens, Johan; Duyster, Justus; Greiner, Jochen; Chalando...

Mark

A qualitative study of the development of health literacy capacities of participants attending a community-based cardiovascular health programme (2018)

McKenna, Verna; Sixsmith, Jane; Barry, Margaret

Mark

Addressing market segmentation and incentives for risk selection: how well does risk equalisation in the Irish private health insurance market work? (2017)

Keegan, Conor; Teljeur, Conor; Turner, Brian; Thomas, Steve

Mark

Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the apollo trial (2018)

Teo, K. K.; Pfeffer, M.; Mancia, G.; O'Donnell, M.; Dagenais, G.; Diaz, R.; Dans, ...

Mark

An evaluation of on-tool shrouds for controlling respirable crystalline silica in restoration stone work (2018)

Mark

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review (2018)

OH, WILLIAM K.; McDERMOTT, DAVID; PORTA, CAMILLO; LEVY, ANTONIN; ELAIDI, REZA; SCOTTE, ...

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review (2018)

OH, WILLIAM K.; McDERMOTT, DAVID; PORTA, CAMILLO; LEVY, ANTONIN; ELAIDI, REZA; SCOTTE, FLORIAN; HAWKINS, ROBERT; CASTELLANO, DANIEL; BELLMUNT, JOAQUIM; RHA, SUN YOUNG; SUN, JONG-MU; NATHAN, PAUL; FEINBERG, BRUCE A.; SCOTT, JEFFREY; McDERMOTT, RAY; AHN, JIN-HEE; WAGSTAFF, JOHN; CHANG, YEN-HWA; OU, YEN-CHUAN; DONNELLAN, PAUL

Abstract:

The aim of this study was to assess the treatment patterns and safety of sunitinib, sorafenib and bevacizumab in real-world clinical settings in US, Europe and Asia. Medical records were abstracted at 18 community oncology clinics in the US and at 21 tertiary oncology centers in US, Europe and Asia for 883 patients 18 years who had histologically/cytologically confirmed diagnosis of advanced RCC and received sunitinib (n=631), sorafenib (n=207) or bevacizumab (n=45) as first-line treatment. No prior treatment was permitted. Data were collected on all adverse events (AEs) and treatment modifications, including discontinuation, interruption and dose reduction. Treatment duration was estimated using Kaplan-Meier analysis. Demographics were similar across treatment groups and regions. Median treatment duration ranged from 6.1 to 10.7 months, 5.1 to 8.5 months and 7.5 to 9.8 months for sunitinib, sorafenib and bevacizumab patients, respectively. Grade 3/4 AEs were experienced by 26.0, 28...

http://hdl.handle.net/10379/13337

Mark

Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland (2015)

Linnane, Barry; Kiernan, Miranda G.; O'Connell, Nuala H.; Kearse, Linda; Dunne, Co...

Mark

Breast-cancer adjuvant therapy with zoledronic acid (2018)

Coleman, Robert E.; Marshall, Helen; Cameron, David; Dodwell, David; Burkinshaw, Roger;...

Breast-cancer adjuvant therapy with zoledronic acid (2018)

Coleman, Robert E.; Marshall, Helen; Cameron, David; Dodwell, David; Burkinshaw, Roger; Keane, Maccon; Gil, Miguel; Houston, Stephen J.; Grieve, Robert J.; Barrett-Lee, Peter J.; Ritchie, Diana; Pugh, Julia; Gaunt, Claire; Rea, Una; Peterson, Jennifer; Davies, Claire; Hiley, Victoria; Gregory, Walter; Bell, Richard

Abstract:

BACKGROUND Data suggest that the adjuvant use of bisphosphonates reduces rates of recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment with zoledronic acid, in addition to standard adjuvant therapy, would improve disease outcomes in such patients. METHODS In this open-label phase 3 study, we randomly assigned 3360 patients to receive standard adjuvant systemic therapy either with or without zoledronic acid. The zoledronic acid was administered every 3 to 4 weeks for 6 doses and then every 3 to 6 months to complete 5 years of treatment. The primary end point of the study was disease-free survival. A second interim analysis revealed that a prespecified boundary for lack of benefit had been crossed. RESULTS At a median follow-up of 59 months, there was no significant between-group difference in the primary end point, with a rate of disease-free survival of 77% in each group (adjusted hazard ratio in the zoledronic acid gro...

http://hdl.handle.net/10379/10843

Mark

Canakinumab treatment for patients with active recurrent or chronic tnf receptor-associated periodic syndrome (traps): an open-label, phase ii study (2018)

Gattorno, Marco; Obici, Laura; Cattalini, Marco; Tormey, Vincent; Abrams, Ken; Davis, N...

Mark

Commonly used disinfectants fail to eradicate salmonella enterica biofilms from food contact surface materials (2018)

Corcoran, M.; Morris, D.; De Lappe, N.; O'Connor, J.; Lalor, P.; Dockery, P.; Corm...

Mark

Comparison of approaches for rational siRNA design leading to a new efficient and transparent method (2007)

Matveeva, Olga; Nechipurenko, Yury; Rossi, Leo; Moore, Barry; Saetrom, Pal; Ogurtsov, A...

Mark

Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals (2018)

Chang, Kah Hoong; Brodie, Rachel; Choong, Mei Ann; Sweeney, Karl J; Kerin, Michael J

Mark

Dialectical behaviour therapy (DBT) in the treatment of borderline personality disorder (2018)

O'Connell, B.; Dowling, Maura

Mark

Differential impact of hormone receptor status on survival and recurrence for her2 receptor-positive breast cancers treated with trastuzumab (2018)

McGuire, Andrew; Kalinina, Olga; Holian, Emma; Curran, Catherine; Malone, Carmel A.; Mc...

Mark

Efficacy of viral load suppression on life expectancy of human immunodeficiency virus patients: a literature review (2020)

Bwambale Kyamakya, Moses; Niranjan, Vikram

Mark

Formulation strategies to improve oral peptide delivery (2016)

Maher, Sam; Ryan, Ben; Duffy, Aoife; Brayden, David James

Mark

Gastrointestinal nematode control practices on lowland sheep farms in ireland with reference to selection for anthelmintic resistance (2018)

Patten, Thomas; Good, Barbara; Hanrahan, James P; Mulcahy, Grace; de Waal, Theo

Mark

Highly sensitive b cell analysis predicts response to rituximab therapy in rheumatoid arthritis (2018)

Dass, Shouvik; Rawstron, Andy C.; Vital, Edward M.; Henshaw, Karen; McGonagle, Dennis; ...

Mark

Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function (2018)

Park, Walter D.; Larson, Timothy S.; Griffin, Matthew D.; Stegall, Mark D.

Mark

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five european countries (2018)

Porta, Camillo; Levy, Antonin; Hawkins, Robert; Castellano, Daniel; Bellmunt, Joaquim; ...

Porta, Camillo; Levy, Antonin; Hawkins, Robert; Castellano, Daniel; Bellmunt, Joaquim; Nathan, Paul; McDermott, Ray; Wagstaff, John; Donnellan, Paul; McCaffrey, John; Vekeman, Francis; Neary, Maureen P.; Diaz, Jose; Mehmud, Faisal; Duh, Mei Sheng

Abstract:

Angiogenesis inhibitors have become standard of care for advanced and/or metastatic renal cell carcinoma (RCC), but data on the impact of adverse events (AEs) and treatment modifications associated with these agents are limited. Medical records were abstracted at 10 tertiary oncology centers in Europe for 291 patients &gt;= 18 years old treated with sunitinib as first-line treatment for advanced RCC (no prior systemic treatment for advanced disease). Logistic regression models were estimated to compare dose intensity among patients who did and did not experience AEs during the landmark periods (18, 24, and 30 weeks). Cox proportional hazard models were used to explore the possible relationship of low-dose intensity (defined using thresholds of 0.7, 0.8, and 0.9) and treatment modifications during the landmark periods to survival. 64.4% to 67.9% of patients treated with sunitinib reported at least one AE of any grade, and approximately 10% of patients experienced at least one...

http://hdl.handle.net/10379/13505